Switch theme
Sign up to access all valuation multiples
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
1996
570
LTM Revenue $1.1B
LTM EBITDA $376M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prestige Consumer Healthcare has a last 12-month revenue of $1.1B and a last 12-month EBITDA of $376M.
In the most recent fiscal year, Prestige Consumer Healthcare achieved revenue of $1.1B and an EBITDA of $374M.
Prestige Consumer Healthcare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prestige Consumer Healthcare valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B | XXX |
| Gross Profit | $621M | $625M | $624M | XXX | XXX |
| Gross Margin | 57% | 55% | 55% | XXX | XXX |
| EBITDA | $359M | $7.9M | $374M | $376M | XXX |
| EBITDA Margin | 33% | 1% | 33% | 33% | XXX |
| Net Profit | $205M | -$82.3M | $209M | XXX | XXX |
| Net Margin | 19% | -7% | 19% | XXX | XXX |
| Net Debt | $1.4B | $1.3B | $1.1B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Prestige Consumer Healthcare's stock price is $85.
Prestige Consumer Healthcare has current market cap of $4.2B, and EV of $5.2B.
See Prestige Consumer Healthcare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $4.2B | XXX | XXX | XXX | XXX | $4.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Prestige Consumer Healthcare has market cap of $4.2B and EV of $5.2B.
Prestige Consumer Healthcare's trades at 4.6x LTM EV/Revenue multiple, and 13.8x LTM EBITDA.
Analysts estimate Prestige Consumer Healthcare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Prestige Consumer Healthcare and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.2B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | XXX | XXX |
| P/E | 18.5x | XXX | XXX | XXX |
| P/E/Growth | 3.3x | XXX | XXX | XXX |
| EV/FCF | 20.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPrestige Consumer Healthcare's NTM/LTM revenue growth is 2%
Prestige Consumer Healthcare's revenue per employee for the last fiscal year averaged $2.0M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Prestige Consumer Healthcare's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Prestige Consumer Healthcare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Prestige Consumer Healthcare and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 4648% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 35% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 25% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prestige Consumer Healthcare acquired XXX companies to date.
Last acquisition by Prestige Consumer Healthcare was XXXXXXXX, XXXXX XXXXX XXXXXX . Prestige Consumer Healthcare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Prestige Consumer Healthcare founded? | Prestige Consumer Healthcare was founded in 1996. |
| Where is Prestige Consumer Healthcare headquartered? | Prestige Consumer Healthcare is headquartered in United States of America. |
| How many employees does Prestige Consumer Healthcare have? | As of today, Prestige Consumer Healthcare has 570 employees. |
| Who is the CEO of Prestige Consumer Healthcare? | Prestige Consumer Healthcare's CEO is Mr. Ronald M. Lombardi. |
| Is Prestige Consumer Healthcare publicy listed? | Yes, Prestige Consumer Healthcare is a public company listed on NYS. |
| What is the stock symbol of Prestige Consumer Healthcare? | Prestige Consumer Healthcare trades under PBH ticker. |
| When did Prestige Consumer Healthcare go public? | Prestige Consumer Healthcare went public in 2005. |
| Who are competitors of Prestige Consumer Healthcare? | Similar companies to Prestige Consumer Healthcare include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Prestige Consumer Healthcare? | Prestige Consumer Healthcare's current market cap is $4.2B |
| What is the current revenue of Prestige Consumer Healthcare? | Prestige Consumer Healthcare's last 12-month revenue is $1.1B. |
| What is the current EBITDA of Prestige Consumer Healthcare? | Prestige Consumer Healthcare's last 12-month EBITDA is $376M. |
| What is the current EV/Revenue multiple of Prestige Consumer Healthcare? | Current revenue multiple of Prestige Consumer Healthcare is 4.6x. |
| What is the current EV/EBITDA multiple of Prestige Consumer Healthcare? | Current EBITDA multiple of Prestige Consumer Healthcare is 13.8x. |
| What is the current revenue growth of Prestige Consumer Healthcare? | Prestige Consumer Healthcare revenue growth between 2023 and 2024 was 0%. |
| Is Prestige Consumer Healthcare profitable? | Yes, Prestige Consumer Healthcare is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
